/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
While earlier attempts were unsuccessful, with Glenmark running into huge losses, there seems to be growing consensus that the drugmaker’s R&D strategy makes it a different company. Perhaps even a valuable one.
On 10 December 2024, Glenmark Pharmaceuticals made a surprise announcement on the stock exchange. The Mumbai-based drugmaker shared clinical trial results from Ichnos Glenmark Innovation, its New York-based biotech arm. The company had achieved a significant breakthrough.
At the 66th annual meeting of the American Society of Hematology in San Diego, Ichnos had presented phase I data for its multispecific antibody targeting relapsed or refractory multiple myeloma (a type of incurable blood cancer). The results? An overall response rate of 75% in 20 patients, with 20% achieving complete remission.
This could make it a vital new drug in a high-growth …
India’s second-largest brokerage by active clients wants to handle IPOs as a merchant banker. But gaining a foothold in the highly competitive sector is easier said than done.
Influence cannot be manufactured through diaspora networks, carefully branded events or political donations. It requires honesty and credibility.
Chinese diplomats to India are saying all the right things for Indian ears, but Beijing’s policy actions are moving in the opposite direction.
